Marksans Pharma Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 09, 2026

Key Highlights

The Latest Trading Price of Marksans Pharma Ltd is ₹ 197.9 as of 08 May 15:30 . The p/e ratio of Marksans Pharma Ltd changed from 8.7 to 26.5 over 5 quarters. This represents a CAGR of 143.77% The p/e ratio of Sanofi India Ltd changed from 30.8 to 0 over 7 quarters. This represents a CAGR of -100.00% The market cap of Marksans Pharma Ltd changed from ₹ 2044 crore to ₹ 10076 crore over 5 quarters. This represents a CAGR of 258.23% The market cap of Sanofi India Ltd changed from ₹ 18578 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The revenue of Marksans Pharma Ltd for the Dec '25 is ₹ 774.57 crore as compare to the Sep '25 revenue of ₹ 741.98 crore. This represent the growth of 4.39% The revenue of Sanofi India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Marksans Pharma Ltd for the Dec '25 is ₹ 180.89 crore as compare to the Sep '25 ebitda of ₹ 166.07 crore. This represent the growth of 8.92% The ebitda of Sanofi India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Marksans Pharma Ltd changed from ₹ 89.07 crore to ₹ 113.69 crore over 7 quarters. This represents a CAGR of 14.97% The net profit of Sanofi India Ltd changed from ₹ 136.6 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The dividend payout of Marksans Pharma Ltd changed from 10.4 % to 19.26 % over 5 quarters. This represents a CAGR of 63.72% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Marksans Pharma Ltd

Marksans Pharma Limited was formerly incorporated as 'Tasc Pharmaceuticals Limited' in April, 1982.
Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited from 10th October, 2005.
The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation.
The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s.
Marksans Pharma Limited (formerly M/s.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Marksans Pharma Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Marksans Pharma Ltd or Sanofi India Ltd?

Market cap of Marksans Pharma Ltd is 8,968 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Marksans Pharma Ltd and Sanofi India Ltd?

The stock performance of Marksans Pharma Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Marksans Pharma Ltd and Sanofi India Ltd?

As of May 9, 2026, the Marksans Pharma Ltd stock price is INR ₹197.9. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Marksans Pharma Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Marksans Pharma Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.